Clinical Trial Update: Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the addition of daclatasvir to standard of care in treatment-naïve hepatitis C patients. The study is completed and results were post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Daclatasvir (daclatasvir)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C Virus | Phase 2 | Status: COMPLETED | Results posted: 2015-10-23